Compare XEL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XEL | INSM |
|---|---|---|
| Founded | 1909 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5B | 41.2B |
| IPO Year | N/A | 2000 |
| Metric | XEL | INSM |
|---|---|---|
| Price | $74.44 | $178.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 21 |
| Target Price | $84.00 | ★ $185.84 |
| AVG Volume (30 Days) | ★ 5.6M | 3.7M |
| Earning Date | 02-05-2026 | 10-30-2025 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $14,228,000,000.00 | $447,022,000.00 |
| Revenue This Year | $13.16 | $43.10 |
| Revenue Next Year | $7.63 | $128.25 |
| P/E Ratio | $22.68 | ★ N/A |
| Revenue Growth | 3.38 | ★ 30.34 |
| 52 Week Low | $62.58 | $60.40 |
| 52 Week High | $83.01 | $212.75 |
| Indicator | XEL | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 40.56 |
| Support Level | $72.54 | $172.65 |
| Resistance Level | $74.29 | $179.33 |
| Average True Range (ATR) | 1.27 | 7.15 |
| MACD | 0.00 | -3.04 |
| Stochastic Oscillator | 39.51 | 37.18 |
Xcel Energy manages utilities serving 3.8 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US, with more than half of its electricity sales coming from carbon-free energy.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.